PROTAC IRAK4 ligand-1 is primarily used in the field of targeted protein degradation, specifically for the IRAK4 protein, which plays a critical role in innate immune signaling pathways. This compound is designed to recruit IRAK4 to an E3 ubiquitin ligase, facilitating its ubiquitination and subsequent degradation by the proteasome. This approach is particularly valuable in research focused on inflammatory diseases, autoimmune disorders, and certain cancers where IRAK4 signaling is dysregulated. By degrading IRAK4, it helps in studying the downstream effects of its inhibition and potentially offers a therapeutic strategy for conditions driven by aberrant IRAK4 activity. Its application extends to drug discovery and preclinical studies, providing insights into the feasibility of targeting IRAK4 for therapeutic intervention.